Printable Test Catalog - OU Medicine

More documents

Recommendations

Info

[CEPHAL] Cephalexin Level SPECIMEN REQUIRED: Frozen serum TUBE OR CONTAINER: Red SPECIAL HANDLING: Collect within 15 minutes of next dose for the TROUGH level; Collect within 15-30 minutes after the end of IV infusion or 45-60 minutes after an IM injection or 90 minutes after oral intake for the PEAK level Do NOT use gel barrier tubes SPECIMEN VOLUME: 1 mL MINIMUM VOLUME: 0.5 mL TEST AVAILABILITY: Daily TURNAROUND TIME: 3-5 days REFERENCE RANGE: Peak: 0.5-18 ug/mL No trough therapeutic range established OTHER NAMES: Biocef; Keflex; Keftab; Panixine; Zartan METHODOLOGY: BioAssay CLINICAL USE: Therapeutic drug monitoring CPT: 80299 [CER] Ceruloplasmin SPECIMEN REQUIRED: Frozen serum TUBE OR CONTAINER: Red, Gold or Green (heparin) SPECIAL HANDLING: Keep specimen on ice while clotting. Prolonged storage at room temperature decreases level SPECIMEN VOLUME: 1 mL MINIMUM VOLUME: 0.1 mL TEST AVAILABILITY: Daily TURNAROUND TIME: 2-5 days REFERENCE RANGE: Male: 16.2-35.6 mg/dL Female: 17.9-53.3 mg/dL METHODOLOGY: Immunologic CLINICAL USE: Evaluation of chronic active hepatitis, cirrhosis and other liver diseases CPT: 82390 [CEREZ] CEREZYME (IMIGLUCERASE) SPECIMEN REQUIRED: Frozen serum TUBE OR CONTAINER: Red or gold SPECIMEN VOLUME: 2 mL MINIMUM VOLUME: 1 mL TEST AVAILABILITY: Daily TURNAROUND TIME: 8-14 days OTHER NAMES: Imiglucerase [CFBGENE] COMPLEMENT FACTOR B GENE SPECIMEN REQUIRED: Whole bloood at room temperature TUBE OR CONTAINER: Lavender (EDTA) SPECIMEN VOLUME: 4 mL MINIMUM VOLUME: 2 mL
TEST AVAILABILITY: Daily TURNAROUND TIME: 3 months METHODOLOGY: Polymerase Chain Reaction (PCR) CPT: 83891; 83894; 83898 x 17; 83904 x 18; 83912 [CFC] CARDIO-FACIO-CUTANEOUS SYNDROM SPECIMEN REQUIRED: Whole blood at room temperature TUBE OR CONTAINER: Lavender (EDTA) or Yellow (ACD) SPECIMEN VOLUME: 5 mL MINIMUM VOLUME: 2 mL TEST INCLUDES: DNA sequencing of exons 6, 11-17 of BRAF gene TEST AVAILABILITY: Daily TURNAROUND TIME: 2-4 weeks REFERENCE RANGE: No mutation detected OTHER NAMES: BRAF Gene Sequencing METHODOLOGY: Polymerase Chain Reaction (PCR) REFLEX TEST INFORMATION: If BRAF gene is negative, testing for MAP2K1, MAP2K2 and KRAS will be reflexed at additional charges CLINICAL USE: Confirmation of clinical diagnosis CPT: 83890; 83891; 83894; 83898 x 7; 83904 x 7; 83912 (BRAF) CPT: 83890; 83891; 83894; 83898 x 9; 83904 x 9; 83912 (TEST #2) [CFC1] HETEROTAXY SYNDROME (CFC1) SPECIMEN REQUIRED: Whole blood at room temperature TUBE OR CONTAINER: Lavender (EDTA) SPECIMEN VOLUME: 5 mL MINIMUM VOLUME: 2 mL TEST AVAILABILITY: Daily TURNAROUND TIME: 2-4 weeks OTHER NAMES: Heterotaxy Syndrome via CFC1 gene Sequencing METHODOLOGY: Polymerase Chain Reaction (PCR) CPT: 83891; 83898 x 6; 83904 x 12; 83912 [CFHDNA] COMPLEMENT FACTOR H DNA SPECIMEN REQUIRED: Whole bloood at room temperature TUBE OR CONTAINER: Lavender (EDTA) SPECIMEN VOLUME: 4 mL MINIMUM VOLUME: 2 mL TEST AVAILABILITY: Daily METHODOLOGY: Polymerase Chain Reaction (PCR) CPT: 83891; 83894; 83898 x 22; 83904 x 22; 83912 [CFHR5] COMPLEMENT FACTOR H-RELATED 5 SPECIMEN REQUIRED: Whole bloood at room temperature TUBE OR CONTAINER: Lavender (EDTA) SPECIMEN VOLUME: 4 mL MINIMUM VOLUME: 2 mL TEST AVAILABILITY: Daily TURNAROUND TIME: 3 months
Page 1 and 2:
Test Catalog OU MEDICAL CENTER Labo
Page 3 and 4:
MINIMUM VOLUME: 20 mL TEST AVAILABI
Page 5 and 6:
OTHER NAMES: Serotonin Metabolite,
Page 7 and 8:
REFERENCE RANGE: < 0.62 mg/g METHOD
Page 9 and 10:
Aciduria, Mitochondrial Acetoacetyl
Page 11 and 12:
MINIMUM VOLUME: 0.3 mL (this volume
Page 13 and 14:
TUBE OR CONTAINER: Red or Lavender
Page 15 and 16:
REFLEX TEST INFORMATION: CPT: 84311
Page 17 and 18:
REFERENCE RANGE: Negative: OTHER NA
Page 19 and 20:
TEST AVAILABILITY: Daily TURNAROUND
Page 21 and 22:
[AL] Aluminum Level SPECIMEN REQUIR
Page 23 and 24:
SPECIMEN REQUIRED: Refrigerated bod
Page 25 and 26:
3gm/sodium/day). SPECIMEN VOLUME: 0
Page 27 and 28:
MINIMUM VOLUME: 0.5 mL TEST AVAILAB
Page 29 and 30:
[ALLPOTWH] ALLERGEN POTATO WHITE [A
Page 31 and 32:
TURNAROUND TIME: 2-9 days REFERENCE
Page 33 and 34:
[ALU] ALUMINUM URINE SPECIMEN REQUI
Page 35 and 36:
TUBE OR CONTAINER: Light Green (hep
Page 37 and 38:
cirrhosis, hepatic failure, acute a
Page 39 and 40:
TURNAROUND TIME: 8 hours REFERENCE
Page 41 and 42:
CPT: 86038 [ANAFL] Body Fluid Anti-
Page 43 and 44:
METHODOLOGY: Radioimmunoassay (RIA)
Page 45 and 46:
peripheral tissues to the liver whe
Page 47 and 48:
through Thursday only SPECIMEN VOLU
Page 49 and 50:
METHODOLOGY: Inductively Coupled Pl
Page 51 and 52:
TURNAROUND TIME: 4-5 days METHODOLO
Page 53 and 54: Testing specimen: 2 transport tubes
Page 55 and 56: SPECIMEN VOLUME: 10 mL (2 tubes) MI
Page 57 and 58: TURNAROUND TIME: 3 days REFERENCE R
Page 59 and 60: SPECIMEN REQUIRED: Whole blood at r
Page 61 and 62: METHODOLOGY: Flow Cytometry CLINICA
Page 63 and 64: TURNAROUND TIME: 10-14 days REFEREN
Page 65 and 66: CLINICAL USE: Detection of spinal f
Page 67 and 68: [BILDT] BILIRUBIN DIRECT AND TOTAL
Page 69 and 70: [BIS] Bismuth Level SPECIMEN REQUIR
Page 71 and 72: SPECIMEN VOLUME: 20 mL MINIMUM VOLU
Page 73 and 74: CPT: 82544; 83788; 84378 [BOP] Bloo
Page 75 and 76: [BRUCM] Brucella abortus IgM Antibo
Page 77 and 78: [BUNFL] Body Fluid Urea Nitrogen SP
Page 79 and 80: some malignancies CPT: 86332 [C3FLD
Page 81 and 82: therapy CPT: 86300 [CA15-3FLD] Body
Page 83 and 84: CPT: 83891; 83898 x 23; 83904 x 23;
Page 85 and 86: Spin in refrigerated centrifuge; se
Page 87 and 88: REFERENCE RANGE: MONO-OLIGOSACCHARI
Page 89 and 90: CLINICAL USE: Evaluate toxicity; mo
Page 91 and 92: [CATALDIS] CATALASE DISTRIBUTION FI
Page 93 and 94: SPECIAL HANDLING: Adjust pH to < 2
Page 95 and 96: CPT: 83891; 83892 x 2; 83894 x 2 ;8
Page 97 and 98: SPECIMEN REQUIRED: Whole blood at r
Page 99 and 100: stool specimen in a tightly sealed
Page 101 and 102: MINIMUM VOLUME: 0.5 mL (pediatric)
Page 103: SPECIMEN VOLUME: 1 mL MINIMUM VOLUM
Page 107 and 108: SPECIMEN VOLUME: 10 mL MINIMUM VOLU
Page 109 and 110: MINIMUM VOLUME: 0.5 mL (0.25-pediat
Page 111 and 112: METHODOLOGY: Micro-Immunofluorescen
Page 113 and 114: CPT: 82542 [CHOLIN] Serum Cholinest
Page 115 and 116: TUBE OR CONTAINER: Sterile containe
Page 117 and 118: REFERENCE RANGE: By report METHODOL
Page 119 and 120: SPECIMEN VOLUME: 0.2 mL MINIMUM VOL
Page 121 and 122: SPECIAL HANDLING: Acidify urine to
Page 123 and 124: SPECIMEN VOLUME: 1 mL MINIMUM VOLUM
Page 125 and 126: TUBE OR CONTAINER: Red or Dark Gree
Page 127 and 128: [CLTN2] CITRULLINEMIA TYPE 2(SLC25A
Page 129 and 130: TURN-AROUND-TIME: 14-21 days METHOD
Page 131 and 132: SPECIMEN REQUIRED: Serum at room te
Page 133 and 134: CPT: 83018 [COCCIAB] Coccidioides A
Page 135 and 136: -Saldino achondrogenesis, Kniest dy
Page 137 and 138: REFERENCE RANGE: IgG: Negative: < 1
Page 139 and 140: TEST AVAILABILITY: Daily METHODOLOG
Page 141 and 142: TUBE OR CONTAINER: EDTA (lavender)
Page 143 and 144: hereditary; Evaluation of progressi
Page 145 and 146: TURNAROUND TIME: OTHER NAMES: CoQ10
Page 147 and 148: TUBE OR CONTAINER: Gold or Light Gr
Page 149 and 150: METHODOLOGY: Complement Fixation (C
Page 155 and 156:
MINIMUM VOLUME: 0.5 mL (serum) 0.5
Page 157 and 158:
Page 159 and 160:
or sterile tube SPECIAL HANDLING: S
Page 161 and 162:
analysis targeting 1.8 million copy
Page 163 and 164:
TUBE OR CONTAINER: Para-Pak C&S ora
Page 165 and 166:
TUBE OR CONTAINER: Sterile containe
Page 167 and 168:
facility. A minimum of two sets of
Page 169 and 170:
MINIMUM VOLUME: 5 mL TEST AVAILABIL
Page 171 and 172:
SPECIMEN REQUIRED: Sputum or swab C
Page 173 and 174:
SPECIMEN VOLUME: 10 mL MINIMUM VOLU
Page 175 and 176:
CLINICAL USE: Isolate and identify
Page 177 and 178:
SPECIAL HANDLING: Indicate source;
Page 179 and 180:
TEST AVAILABILITY: Referral to Focu
Page 181 and 182:
[CULSINAA] Sinus A/An Cult & Gram S
Page 183 and 184:
screen for colonization by Group B
Page 185 and 186:
ORDERING MODULE: MIC TEST INCLUDES:
Page 187 and 188:
METHODOLOGY: Culture CLINICAL USE:
Page 189 and 190:
[CYAN] Cyanide SPECIMEN REQUIRED: R
Page 191 and 192:
[CYP2C219] CLOPIDOGREL CYPC219 GENO
Page 193 and 194:
REFERENCE RANGE: < 0.2 nmoles half
Page 195 and 196:
CPT: 83890; 83891, 83894; 83898 x 8
Page 197 and 198:
SPECIMEN VOLUME: 3 mL MINIMUM VOLUM
Page 199 and 200:
CLINICAL USE: Monitor therapeutic l
Page 201 and 202:
Page 203 and 204:
[DNADAB] Anti-Double Strand DNA Ant
Page 205 and 206:
(LC/MS-MS) CLINICAL USE: Evaluate t
Page 207 and 208:
TEST AVAILABILITY: Monday-Thursday
Page 209 and 210:
TURNAROUND TIME: 1-4 days REFERENCE
Page 211 and 212:
Page 213 and 214:
[EBVEACSF] Epstein-Barr Early Antig
Page 215 and 216:
[EDAR] ECTODERMAL DYSPL (EDAR GENE)
Page 217 and 218:
[EHISAB] Entamoeba histolytica Anti
Page 219 and 220:
(A, F, S, and C), evaluate hemolyti
Page 221 and 222:
METHODOLOGY: Indirect fluorescent a
Page 223 and 224:
(PCR-RT) CLINICAL USE: Detection of
Page 225 and 226:
[ESTRI] Estriol Level SPECIMEN REQU
Page 227 and 228:
CPT: 82690 [ETHGLY] Ethylene Glycol
Page 229 and 230:
Page 231 and 232:
SPECIMEN REQUIRED: Frozen plasma TU
Page 233 and 234:
TUBE OR CONTAINER: Blue (Citrate) S
Page 235 and 236:
estriction enzyme digestion and gel
Page 237 and 238:
Page 239 and 240:
[FAPDD] FAP DUPLICATION/DELETION SP
Page 241 and 242:
efore specimen is drawn SPECIMEN VO
Page 243 and 244:
SPECIMEN REQUIRED: Amniotic fluid T
Page 245 and 246:
SPECIMEN REQUIRED: Whole blood at r
Page 247 and 248:
[FKTN] FUKUTIN (FKTN) GENE SEQUENCI
Page 249 and 250:
[FLT3] FLT3 INTERNAL TANDEM DUP SPE
Page 251 and 252:
OTHER NAMES: Prolixin; Permitil MET
Page 253 and 254:
METHODOLOGY: Electrochemiluminescen
Page 255 and 256:
TURNAROUND TIME: 4 weeks OTHER NAME
Page 257 and 258:
and fructose-1,6 diphosphatase defi
Page 259 and 260:
[FTACSF] CSF Treponema pallidum Ab
Page 261 and 262:
[FUNSENS] FUNGUS SENSITIVITY TEST O
Page 263 and 264:
Page 265 and 266:
[GABRG2] g-AMINOBUTYRIC RECEPT GAMM
Page 267 and 268:
REFERENCE RANGE: METHODOLOGY: Spect
Page 269 and 270:
[GAST] Gastrin SPECIMEN REQUIRED: F
Page 271 and 272:
CPT: 83891; 83894; 83898 x 25; 8390
Page 273 and 274:
OTHER NAMES: HGH; Human Growth Horm
Page 275 and 276:
REFERENCE RANGE: IgA: Negative: 0-1
Page 277 and 278:
CPT: 82943 [GLUCSF] CSF Glucose SPE
Page 279 and 280:
SPECIMEN REQUIRED: Frozen serum or
Page 281 and 282:
TURNAROUND TIME: 2-6 days METHODOLO
Page 283 and 284:
Page 285 and 286:
SPECIMEN VOLUME: 5 mL each tube MIN
Page 287 and 288:
SPECIMEN REQUIRED: Whole blood; Liv
Page 289 and 290:
food and liquids (even water) durin
Page 291 and 292:
Page 293 and 294:
SPECIMEN REQUIRED: Refrigerated ser
Page 295 and 296:
gene. Disease progression and respo
Page 297 and 298:
Page 299 and 300:
TUBE OR CONTAINER: Red or Gold SPEC
Page 301 and 302:
METHODOLOGY: Atomic absorption spec
Page 303 and 304:
[HEMAINV] HEMOPHILIA A INVERSION (D
Page 305 and 306:
Page 307 and 308:
coagulant to blood ratio; Invert ge
Page 309 and 310:
TURNAROUND TIME: 7-10 days REFERENC
Page 311 and 312:
OTHER NAMES: Free Hemoglobin; Hgb S
Page 313 and 314:
TURNAROUND TIME: 3-4 weeks REFERENC
Page 315 and 316:
1 mL (CSF-frozen) MINIMUM VOLUME: 3
Page 317 and 318:
MINIMUM VOLUME: 0.5 mL TEST INCLUDE
Page 319 and 320:
Heparin-Induced Thrombocytopenia Ab
Page 321 and 322:
REFLEX TEST INFORMATION: CLINICAL U
Page 323 and 324:
Page 325 and 326:
[HOMOCUP] UR HOMOCYSTEINE PANEL SPE
Page 327 and 328:
TUBE OR CONTAINER: Lavender (EDTA)
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
CPT: 82570; 83150 [HWS] ECTODERMAL
Page 335 and 336:
METHODOLOGY: Polymerase Chain React
Page 337 and 338:
[IDIHIVINTEG] HIV Integrase Inhibit
Page 339 and 340:
[IEPRAN] UR IMMUNOELECTROPHOR RANDO
Page 341 and 342:
performed on a lipemic sample SPECI
Page 343 and 344:
Page 345 and 346:
CPT: 82784 [IGGFLD] Body Fluid Immu
Page 347 and 348:
Page 349 and 350:
MINIMUM VOLUME: 0.2 mL in two separ
Page 351 and 352:
Page 353 and 354:
[INT10] Interleukin 10 (IL-10) SPEC
Page 355 and 356:
TUBE OR CONTAINER: Red, Gold or Lav
Page 357 and 358:
METHODOLOGY: Liquid Chromatography/
Page 359 and 360:
OTHER NAMES: JAK2 Mutation METHODOL
Page 361 and 362:
Page 363 and 364:
REFERENCE RANGE: No mutation detect
Page 365 and 366:
Page 367 and 368:
container or between two microscope
Page 369 and 370:
[L1CAM] L1CAM MUTATION SPECIMEN REQ
Page 371 and 372:
OTHER NAMES: HPL; Human chorionic s
Page 373 and 374:
myelofibrosis with myeloid metaplas
Page 375 and 376:
Page 377 and 378:
[LDHPT] Peritoneal Fluid LDH SPECIM
Page 379 and 380:
Separate from cells within 45 minut
Page 381 and 382:
[LEP] Leptin SPECIMEN REQUIRED: Fro
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
[LISTAB] Listeria Antibody SPECIMEN
Page 389 and 390:
TEST AVAILABILITY: Daily OTHER NAME
Page 391 and 392:
[LQTS] LONG QT SYNDROME SPECIMEN RE
Page 393 and 394:
TUBE OR CONTAINER: Red or Gold SPEC
Page 395 and 396:
SPECIAL HANDLING: Specimen must arr
Page 397 and 398:
[MACAMY] MACROAMYLASE SPECIMEN REQU
Page 399 and 400:
Page 401 and 402:
loci CLINICAL USE: Ensure accurate
Page 403 and 404:
TURNAROUND TIME: 4-6 weeks OTHER NA
Page 405 and 406:
1.11 AU or greater: Positive METHOD
Page 407 and 408:
Do NOT collect specimen in gel barr
Page 409 and 410:
Page 411 and 412:
CPT: 82131 [METHIOU] Urine Methioni
Page 413 and 414:
SPECIMEN REQUIRED: Refrigerated uri
Page 415 and 416:
lock MINIMUM VOLUME: Two unstained
Page 417 and 418:
[MICMISC] Miscellaneous Microbiolog
Page 419 and 420:
[MICSPOR] Microsporidium Smear SPEC
Page 421 and 422:
Page 423 and 424:
REFERENCE RANGE: Negative METHODOLO
Page 425 and 426:
CLINICAL USE: Detects sequence vari
Page 427 and 428:
Page 429 and 430:
CLINICAL USE: Determine immunity to
Page 431 and 432:
SPECIMEN REQUIRED: Serum at room te
Page 433 and 434:
METHODOLOGY: Polymerase Chain React
Page 435 and 436:
OTHER NAMES: Hypertrophic Cardiomyo
Page 437 and 438:
secretion or other diseases involvi
Page 439 and 440:
SPECIMEN REQUIRED: Liquid stool TUB
Page 441 and 442:
METHODOLOGY: Polyermase Chain React
Page 443 and 444:
SPECIMEN REQUIRED: Frozen plasma TU
Page 445 and 446:
TEST AVAILABILITY: Monday - Thursda
Page 447 and 448:
TUBE OR CONTAINER: Dark green (hepa
Page 449 and 450:
[NOMAR] Nomarski Prep [NORDIAZ] Nor
Page 451 and 452:
SPECIMEN REQUIRED: Refrigerated who
Page 453 and 454:
OTHER NAMES: N-Telopeptide crosslin
Page 455 and 456:
[OCCBLDG] Gastric Occult Blood SPEC
Page 457 and 458:
TEST INCLUDES: CSF and serum oligoc
Page 459 and 460:
[ORGQNT] ORGANIC ACIDS QUANTITATIVE
Page 461 and 462:
Page 463 and 464:
(LC/MS/MS) CLINICAL USE: Therapeuti
Page 465 and 466:
TEST AVAILABILITY: Daily REFERENCE
Page 467 and 468:
TEST INCLUDES: Anti-Neuronal Nuclea
Page 469 and 470:
[PARVPCR] Parvovirus B19 DNA (PCR)
Page 471 and 472:
cannot be reliably evaluated SPECIM
Page 473 and 474:
[PDHA1] PYRUV DEHYDROGENASE DEFICIE
Page 475 and 476:
MINIMUM VOLUME: 1.5 mL (this volume
Page 477 and 478:
testing) TEST AVAILABILITY: Daily T
Page 479 and 480:
[PEDIGFBP1] Insulin-like GF Binding
Page 481 and 482:
TUBE OR CONTAINER: Red, Gold, Laven
Page 483 and 484:
SPECIMEN REQUIRED: Fibroblasts at r
Page 485 and 486:
Page 487 and 488:
Page 489 and 490:
Page 491 and 492:
Page 493 and 494:
[PIN] Pinworm Exam SPECIMEN REQUIRE
Page 495 and 496:
TUBE OR CONTAINER: Blue (Citrate) S
Page 497 and 498:
SPECIMEN REQUIRED: Whole blood bloo
Page 499 and 500:
REFERENCE RANGE: Normal - no duplic
Page 501 and 502:
REFERENCE RANGE: Erythritol: 55 - 1
Page 503 and 504:
fluorometric detection CLINICAL USE
Page 505 and 506:
OTHER NAMES: Noxafil METHODOLOGY: H
Page 507 and 508:
[PRIM] PRIMIDONE/PHENOBARBITAL SPEC
Page 509 and 510:
TUBE OR CONTAINER: Light Green (hep
Page 511 and 512:
REFERENCE RANGE: FEP, blood: enviro
Page 513 and 514:
REFERENCE RANGE: None established M
Page 515 and 516:
[PS1] ADMARK PS-1 ANALYSIS SPECIMEN
Page 517 and 518:
times to prevent clotting Send to l
Page 519 and 520:
Send to lab immediately or centrifu
Page 521 and 522:
Testing volume: 1 mL of PLASMA TEST
Page 523 and 524:
TURNAROUND TIME: 3 weeks METHODOLOG
Page 525 and 526:
interferon-gamma production with de
Page 527 and 528:
Page 529 and 530:
MINIMUM VOLUME: 1 mL (this volume d
Page 531 and 532:
Page 533 and 534:
Page 535 and 536:
[RIBCSF] Ribosomal P Protein Antibo
Page 537 and 538:
no additional charge CLINICAL USE:
Page 539 and 540:
OTHER NAMES: Measles antibodies MET
Page 541 and 542:
MINIMUM VOLUME: 2 mL (whole blood)
Page 543 and 544:
SPECIMEN REQUIRED: Fibroblasts at r
Page 545 and 546:
MINIMUM VOLUME: 10 mL TEST AVAILABI
Page 547 and 548:
VOLUME: 2 flasks METHODOLOGY: Immun
Page 549 and 550:
SPECIMEN VOLUME: 10 mL MINIMUM VOLU
Page 551 and 552:
REFERENCE RANGE: Environmental expo
Page 553 and 554:
TURNAROUND TIME: 6-12 days METHODOL
Page 555 and 556:
same day as collected SPECIMEN VOLU
Page 557 and 558:
(testing) TEST INCLUDES: IgG antibo
Page 559 and 560:
METHODOLOGY: Indirect fluorescent a
Page 561 and 562:
[SMTHAB] Anti-Smooth Muscle Antibod
Page 563 and 564:
Page 565 and 566:
TUBE OR CONTAINER: Transfer tube SP
Page 567 and 568:
METHODOLOGY: Flow cytometry [STERAB
Page 569 and 570:
SPECIMEN VOLUME: 300 mL (2 aliquots
Page 571 and 572:
[STRONGG] Strongyloides IgG Antibod
Page 573 and 574:
[SUCCINYL] Urine Succinylacetone SP
Page 575 and 576:
Glyburide, Tolazamide, Tolbutamide
Page 577 and 578:
CPT: 84481 [T3REV] Reverse Triiodot
Page 579 and 580:
[TACRO] Tacrolimus (Prograf) Level
Page 581 and 582:
euthyroid individuals who have norm
Page 583 and 584:
TURNAROUND TIME: 24 hours METHODOLO
Page 585 and 586:
REFERENCE RANGE: Age specific METHO
Page 587 and 588:
Page 589 and 590:
TUBE OR CONTAINER: Red or Dark gree
Page 591 and 592:
Send list of other antibiotics pati
Page 593 and 594:
METHODOLOGY: Polymerase chain react
Page 595 and 596:
Page 597 and 598:
[TOXOA] Toxoplasma IgA Antibody SPE
Page 599 and 600:
Page 601 and 602:
[TRANSF] Transferrin SPECIMEN REQUI
Page 603 and 604:
REFERENCE RANGE: < 5 pg/mL METHODOL
Page 605 and 606:
REFERENCE RANGE: None established M
Page 607 and 608:
METHODOLOGY: Chemiluminescence CLIN
Page 609 and 610:
Page 611 and 612:
TURNAROUND TIME: 2-4 Days METHODOLO
Page 613 and 614:
METHODOLOGY: Enzyme-linked immunoso
Page 615 and 616:
REFLEX TEST INFORMATION: A urine cu
Page 617 and 618:
Page 619 and 620:
[UR FLUORIDE] UR FLUORIDE SPECIMEN
Page 621 and 622:
Page 623 and 624:
MINIMUM VOLUME: 30 mL TEST INCLUDES
Page 625 and 626:
METHODOLOGY: Direct Fluorescent ant
Page 627 and 628:
TEST AVAILABILITY: Monday-Saturday
Page 629 and 630:
SPECIMEN REQUIRED: Serum TUBE OR CO
Page 631 and 632:
CLINICAL INFORMATION: Aid in the di
Page 633 and 634:
will be processed but not stained a
Page 635 and 636:
quantitative test at an additional
Page 637 and 638:
REFERENCE RANGE: Negative METHODOLO
Page 639 and 640:
3. Place the tubing in the nasophar
Page 641 and 642:
the freshest lesion or vesicle (dew
Page 643 and 644:
SPECIMEN REQUIRED: Refrigerated spe
Page 645 and 646:
TUBE OR CONTAINER: Viral transport
Page 647 and 648:
Page 649 and 650:
CLINICAL USE: Rapid identification
Page 651 and 652:
5. After or before doing the wash,
Page 653 and 654:
poor or if the FA is negative. The
Page 655 and 656:
viral transport media tube. Refrige
Page 657 and 658:
[VITA] Vitamin A Level SPECIMEN REQ
Page 659 and 660:
[VITB5] Pantothenic Acid Level SPEC
Page 661 and 662:
CLINICAL USE: Rule out vitamin D de
Page 663 and 664:
METHODOLOGY: Liquid chromatography/
Page 665 and 666:
Page 667 and 668:
Page 669 and 670:
clumps of mucous; spread the specim
Page 671 and 672:
1. Patient should not have urinated
Page 673 and 674:
[VPGCDNAP] N. GONORRHOEAE BY PCR SP
Page 675 and 676:
Page 677 and 678:
Nasopharyngeal wash+NP instructions
Page 679 and 680:
TEST AVAILABILLTIY: Monday-Saturday
Page 681 and 682:
port medium or have the patient gar
Page 683 and 684:
a good epithelial cell scraping of
Page 685 and 686:
SPECIMEN REQUIRED: Refrigerated spe
Page 687 and 688:
[VW2B] VON WILLEBRAND TYPE 2B BINDI
Page 689 and 690:
SPECIAL HANDLING: Must be received
Page 691 and 692:
TEST AVAILABILITY: Daily OTHER NAME
Page 693 and 694:
[VZVPCR] Varicella-Zoster Virus DNA
Page 695 and 696:
Page 697 and 698:
device SPECIAL HANDLING: A delay of
Page 699 and 700:
Page 701 and 702:
Discard this sample. Collect urine
Page 703 and 704:
TEST AVAILABILITY: Daily REFERENCE
show all

Printable Test Catalog - OU Medicine

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?